You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.
The two-year award will fund development and commercialization of the firm's HLS-Catch platform and follows a previous grant of $191,535.
Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.
The firm will work with investigators from the University of North Carolina at Chapel Hill and the University of Virginia to validate its AIR system in CRISPR workflows.
The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
With several SBIR grants from the NIH, the firm is also using its Liquid Scan platform to identify neonatal trophoblast cells in maternal blood samples.
Omics Data Automation, founded by creators of the Intel-OHSU Collaborative Cancer Cloud, has also created an open-source community for users of the Broad's GenomicsDB.
DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.
With an SBIR Phase II grant in hand, Michigan startup Parabricks is adding both speed and AI to variant calling as it eyes a Series A round next year.
In addition to the federal grant, the startup has received $125,000 from a Michigan technology fund to help commercialize its GPU-based analysis platform.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.